Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Preferred Stock Liabilities: 2012-2025

Historic Preferred Stock Liabilities for Ani Pharmaceuticals (ANIP) over the last 3 years, with Jun 2025 value amounting to $24.9 million.

  • Ani Pharmaceuticals' Preferred Stock Liabilities changed negligibly% to $24.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $24.9 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $24.9 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q2 2025, Ani Pharmaceuticals' Preferred Stock Liabilities stood at $24.9 million, which was down 0.00% from $24.9 million recorded in Q1 2025.
  • Ani Pharmaceuticals' 5-year Preferred Stock Liabilities high stood at $24.9 million for Q4 2021, and its period low was $24.9 million during Q4 2021.
  • Moreover, its 3-year median value for Preferred Stock Liabilities was $24.9 million (2025), whereas its average is $24.9 million.